As suggested by Xue et al., 6-month replacement therapy with GH may be beneficial for liver enzymes and may also improve obesity-related other cardiovascular and metabolic complications typically associated with NAFLD and NASH [65]. The gene discussed is GH1; the disease is metabolic dysfunction-associated steatohepatitis.